Strain clinical presentation

The degradation of phenylmercuric acetate to benzene, methylmercuric chloride to methane, and ethylmercuric chloride to ethane and Hg + is apparently carried out by different enzymes from the plasmid-carrying Escherichia coli strain K12 (R831) (Schottel 1978) and Pseudomonas sp. Resistance to organic mercury compounds has also been found in clinical isolates of nontuber-culous, rapidly growing mycobacteria (Steingrube et al. 1991) and can present a challenge in the clinical environment. 

Type III (immune complex related disease) reactions have been demonstrated by the presence of proteinuria and immune complex deposits in the kidneys of the Brown-Norway, Lewis, and PVG/C rat strains. However, susceptibility to the deposition and the subsequent lesions (glomerulamephritis) are often variable and dependent on the strain (Bigazzi, 1985). For example, despite the appearance of clinical signs and proteinuria, after two-months administration of mercuric chloride, detectable levels of circulating antinuclear autoantibodies can no longer be observed in the Brown-Norway strain (Bellon et al., 1982). By contrast, in PVG/C rats administered mercuric chloride, immune complex deposition and antinuclear autoantibodies are present for longer periods of time however, proteinurea is not observed (Weeping et al., 1978). 

Zanamivir (Relenza) is a neuraminidase inhibitor with activity against influenza A and B strains. Like oseltamivir, zanamivir is a reversible competitive antagonist of viral neuraminidase. It inhibits the release of progeny virus, causes viral aggregation at the cell surface, and impairs viral movement through respiratory secretions. Resistant variants with hemagglutinin and/or neuraminidase mutations have been produced in vivo however, clinical resistance to zanamivir is quite rare at present. 

Chromosomal metallo-beta-lactamases that hydrolyze carbapenem antibiotics, such as imipenem, meropenem, or biapenem, are present in some Stenotro-phomonas, Bacteroides, andAeromonas strains [26], Some clinical/5, aeruginosa and Serratia marcescens isolates have a plasmid that carries metallo-beta-lactamase genes [26], These enzymes are not inactivated by inhibitors of serine-based beta-lactamases such as clavulanic acid or sulbactam analogs. Enzyme-... 

---